Welcome to our dedicated page for Ofs Credit Company SEC filings (Ticker: OCCIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the CLO cash-flow tests, asset-coverage ratios or interest-rate sensitivities buried deep inside OFS Credit Company Inc. (OCCIO) filings can take hours. Structured-credit portfolios generate pages of footnotes that make a 10-K feel more like a loan indenture than an annual report. If you have ever Googled “OFS Credit Company SEC filings explained simply” or asked, “Where do I locate OFS Credit Company quarterly earnings report 10-Q filing?” you know the challenge.
Stock Titan solves it. Our AI reads every new document the moment it hits EDGAR and delivers plain-English highlights—whether you are scanning an 8-K material event, a proxy statement on executive compensation, or the latest “OFS Credit Company insider trading Form 4 transactions”. Toggle from the full PDF to an AI-powered summary that pinpoints CLO fair-value marks, dividend coverage data and segment exposure. Real-time alerts ensure you never miss “OFS Credit Company Form 4 insider transactions in real time”, the next “OFS Credit Company 8-K material events explained”, or an amendment that tweaks leverage covenants.
All filing types are here in one place: the annual report 10-K simplified, each “OFS Credit Company quarterly earnings report 10-Q filing”, every Form 4 executive stock transaction, and shelf-registration S-3 statements that fund new credit investments. Use our expert analysis to (1) track insider buying before dividend announcements, (2) compare quarter-over-quarter CLO equity returns, and (3) monitor OCCIO note covenants with confidence. Understanding OFS Credit Company SEC documents with AI turns complex disclosures into actionable knowledge—so you can focus on making informed credit and income decisions, not parsing legal prose.
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) filed a Form 8-K reporting two key developments. Under Item 1.01 the Company exercised its contractual right, effective June 27 2025, to terminate the Licensing Agreement with Ocuphire Pharma, Inc. (now Opus Genetics) that had originally been signed on June 16 2021. The filing does not disclose termination fees, financial considerations, or specific reasons for the decision.
Item 7.01 references a press release dated July 1 2025 (Exhibit 99.1) announcing a "strategic portfolio review and pipeline realignment" intended to maximize shareholder value. No operational details, timelines, or updated guidance are included in the 8-K; the press release itself is incorporated by reference but not reproduced in the filing.
The document lists three exhibits—10.1 Termination Agreement, 99.1 Press Release, and 104 iXBRL cover page—and contains no pro-forma financial statements, earnings data, or revised forecasts. As such, investors are informed that Processa has ended one partnered program and is evaluating its development priorities, but the quantitative impact on the Company’s pipeline, cash runway, or future milestones remains undisclosed.